If you have been wondering whether DENTSPLY SIRONA is a beaten down bargain or a value trap, you are not alone. This is exactly what we are going to unpack. The stock has bounced 2.3% over the last ...
Global Sales: $904 million, a decrease of 5% as reported or negative 8% on a constant currency basis. Adjusted EBITDA: 18.4%, up 50 basis points versus prior year. Non-GAAP Earnings Per Share: $0.37, ...
SAN FRANCISCO--(BUSINESS WIRE)--National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Dentsply Sirona Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) who ...
Management reaffirmed the full-year 2025 guidance for organic sales to decline by 2%-4% and adjusted EPS to remain in the range of $1.80 to $2. Reported sales guidance was revised upward to $3.6 ...
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DENTSPLY SIRONA Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) and ...
DENTSPLY SIRONA Inc. announced that it will hold an investor conference call and live webcast on August 7, 2025, at 8:30 am ET to discuss its financial results for the second quarter of fiscal year ...
In the last three months, 9 analysts have published ratings on Dentsply Sirona (NASDAQ:XRAY), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise ...
CEO Simon Campion reported that Dentsply Sirona achieved organic growth in two out of three global regions during Q1 2025. Imaging and Wellspect Healthcare performed strongly, with imaging showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results